Effect of Helicobacter pylori on gastric somatostatin in duodenal ulcer disease

SF Moss, J Calam, S Legon, AE Bishop, JM Polak - The Lancet, 1992 - Elsevier
SF Moss, J Calam, S Legon, AE Bishop, JM Polak
The Lancet, 1992Elsevier
Infection of the gastric antrum by Helicobacter pylori is associated with recurrent duodenal
ulcer disease but the mechanism of ulcerogenesis is unclear. Since pathways inhibiting
gastric secretion are defective in patients with duodenal ulcers, we investigated whether H
pylori interferes with the normal gastric inhibition that is mediated by somatostatin. We
studied 28 patients with active duodenal ulcers in whom H pylori was eradicated
successfully. In 18 patients, we measured the density of antral somatostatin-immunoreactive …
Abstract
Infection of the gastric antrum by Helicobacter pylori is associated with recurrent duodenal ulcer disease but the mechanism of ulcerogenesis is unclear. Since pathways inhibiting gastric secretion are defective in patients with duodenal ulcers, we investigated whether H pylori interferes with the normal gastric inhibition that is mediated by somatostatin. We studied 28 patients with active duodenal ulcers in whom H pylori was eradicated successfully. In 18 patients, we measured the density of antral somatostatin-immunoreactive cells and in a further 10 subjects, the amount of somatostatin mRNA before and after eradication of H pylori was determined. After eradication, the median density of somatostatin-immunoreactive cells increased significantly from 9 (range 3-47) to 19 (6-57) cells per mm muscularis mucosa (p=0·025). The median somatostatin mRNA/rRNA ratio increased from 50 (25-160) to 95 (40-180) (p=0·01). The number of gastrin cells and quantity of gastrin mRNA did not change significantly. Our results suggest that in duodenal ulcer disease, gastric secretory function is disinhibited through the suppression of mucosal somatostatin.
Elsevier